Form 4: Relmada Therapeutics CEO Sergio Traversa Increases Stake in Company
SEC Form 4
Relmada Therapeutics CEO Sergio Traversa has been actively purchasing company stock on the open market, significantly increasing his holdings.
Summary
- Sergio Traversa, the CEO of Relmada Therapeutics, has been buying shares of the company's common stock.
- On May 16, 2025, he acquired 172,314 shares at a weighted average price of $0.4496, with prices ranging from $0.4485 to $0.4564 per share.
- On May 19, 2025, he purchased an additional 30,000 shares at a weighted average price of $0.4998, with prices ranging from $0.4998 to $0.50 per share.
- On May 20, 2025, Traversa acquired 147,686 shares at a weighted average price of $0.5569, with prices ranging from $0.53 to $0.59 per share.
- Following these transactions, Traversa directly owns 734,024 shares of Relmada Therapeutics common stock.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the CEO is increasing his stake in the company, which is generally viewed favorably by investors.
Positives
- The CEO's increased investment in the company may signal confidence in Relmada Therapeutics' future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases as a positive signal, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Sergio Traversa purchased 172,314 shares of common stock at a weighted average price of $0.4496. |
| 05/19/2025 | Sergio Traversa purchased 30,000 shares of common stock at a weighted average price of $0.4998. |
| 05/20/2025 | Sergio Traversa purchased 147,686 shares of common stock at a weighted average price of $0.5569. |
Keywords
Relmada Therapeutics, Sergio Traversa, stock purchase, insider trading, RLMD, CEO, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.